Transwell Biotech

Executive Summary

Transwell Biotech, founded in 2020 and headquartered in Taipei, Taiwan, specializes in advanced cell‑culture and assay platforms, including Transwell™ inserts, 3‑D tissue models, and organ‑on‑a‑chip systems. The company leverages proprietary membrane technologies to enable high‑throughput screening and preclinical toxicology studies, positioning itself as a key enabler of drug discovery across therapeutic areas. With a team of 10–50 employees, Transwell addresses the growing demand for physiologically relevant in vitro models that reduce reliance on animal testing and improve predictivity of drug candidates. Its platforms are widely used in academic labs and biopharma R&D, offering scalable solutions for compound screening, safety assessment, and mechanistic studies. As the organ‑on‑a‑chip market expands, Transwell is well‑positioned to capture share through its differentiated membrane-based technology and cost‑competitive manufacturing in Asia. The company operates in a niche but rapidly growing segment, supported by Taiwan's strong semiconductor and biomedical engineering ecosystem. While still early‑stage, Transwell's focus on high‑quality research tools and its founder's expertise in membrane science provide a solid foundation for future growth. The company's ability to secure partnerships and expand its product portfolio will be critical to scaling its commercial footprint.

Upcoming Catalysts (preview)

• Q4 2026Launch of next‑generation organ‑on‑a‑chip platform60% success
• H1 2027Strategic partnership with a top‑20 pharma for drug screening50% success
• Q3 2026Series A funding round closing70% success